▎Tirzepatid Overview
Tirzepatid, as the first dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is capable of regulating blood glucose levels. Activation of the GLP-1 receptor stimulates insulin secretion and inhibits the release of glucagon, while activation of the GIP receptor enhances insulin sensitivity and insulin secretion. Additionally, Tirzepatid can delay gastric emptying, induce a sense of satiety, reduce food intake, and consequently contribute to weight loss. Moreover, it has the ability to elevate adiponectin levels, thereby improving insulin sensitivity and lipid metabolism.
Clinical trials have evidenced that, in comparison with single GLP-1 agonists, Tirzepatid is more efficacious in blood glucose control and can significantly decrease the levels of glycated hemoglobin. It has demonstrated remarkable efficacy in weight loss, making it a viable option for the treatment of obesity. The once-weekly injection regimen not only enhances patients' medication adherence but also is associated with fewer adverse effects. Meanwhile, it exerts beneficial effects on blood pressure and lipid profiles, suggesting potential cardioprotective properties.
In summary, by virtue of its innovative mechanism of action and favorable therapeutic outcomes, Tirzepatid offers novel treatment alternatives for patients with type 2 diabetes mellitus and obesity, holding the promise of improving their quality of life and overall health status.
